Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Liabilities and Shareholders Equity: 2023-2025

Historic Liabilities and Shareholders Equity for Upstream Bio (UPB) over the last 1 years, with Sep 2025 value amounting to $391.2 million.

  • Upstream Bio's Liabilities and Shareholders Equity rose 68.11% to $391.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year change of. This contributed to the annual value of $481.7 million for FY2024, which is 311.03% up from last year.
  • Upstream Bio's Liabilities and Shareholders Equity amounted to $391.2 million in Q3 2025, which was down 6.97% from $420.5 million recorded in Q2 2025.
  • Over the past 5 years, Upstream Bio's Liabilities and Shareholders Equity peaked at $481.7 million during Q4 2024, and registered a low of $117.2 million during Q4 2023.
  • For the 3-year period, Upstream Bio's Liabilities and Shareholders Equity averaged around $349.9 million, with its median value being $405.9 million (2025).
  • Data for Upstream Bio's Liabilities and Shareholders Equity shows a peak YoY spiked of 311.03% (in 2024) over the last 5 years.
  • Upstream Bio's Liabilities and Shareholders Equity (Quarterly) stood at $117.2 million in 2023, then soared by 311.03% to $481.7 million in 2024, then soared by 68.11% to $391.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $391.2 million for Q3 2025, versus $420.5 million for Q2 2025 and $456.2 million for Q1 2025.